MARKETSQUIET
15 days ago
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
SIGNALSMONITORMARKETS
What's happening
SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 1 Oct 2026, 20:00 UTC. The headline in use is “Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular…”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
Reported by 1 outlet
- Seeking Alpha